Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/173689
Title: | Exogenous hormone use and cutaneous melanoma risk in women: The European Prospective Investigation into Cancer and Nutrition |
Author: | Cervenka, Iris Al Rahmoun, Marie Mahamat-Saleh, Yahya Fournier, Agnès Boutron-Ruault, Marie-Christine Severi, Gianluca Caini, Saverio Palli, Domenico Ghiasvand, Reza Veierod, Marit B. Botteri, Edoardo Tjønneland, Anne Olsen, Anja Fortner, Renée T. Kaaks, Rudolf Schulze, Matthias B. Panico, Salvatore Trichopoulou, Antonia Dessinioti, Clio Niforou, Katerina Sieri, Sabina Tumino, Rosario Sacerdote, Carlotta Bueno de Mesquita, H. Bas Sandanger, Torkjel M. Colorado Yohar, Sandra Sánchez, Maria J. Gil Majuelo, Leire Luján Barroso, Leila Ardanaz, Eva Merino, Susana Isaksson, Karolin Butt, Salma Tunå Ljuslinder, Infrid Jansson, Malin Travis, Ruth C. Khaw, Kay-Tee Weiderpass, Elisabete Dossus, Laure Rinaldi, Sabina Kvaskoff, Marina |
Keywords: | Càncer de pell Dones Nutrició Skin cancer Women Nutrition |
Issue Date: | 15-Jun-2020 |
Publisher: | Wiley |
Abstract: | Evidence suggests an influence of sex hormones on cutaneous melanoma risk, but epidemiologic findings are conflicting. We examined the associations between use of oral contraceptives (OCs) and menopausal hormone therapy (MHT) and melanoma risk in women participating in the European Prospective Investigation into Cancer and Nutrition (EPIC). EPIC is a prospective cohort study initiated in 1992 in 10 European countries. Information on exogenous hormone use at baseline was derived from country‐specific self‐administered questionnaires. We used Cox proportional hazards regression models to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). Over 1992-2015, 1,696 melanoma cases were identified among 334,483 women, whereof 770 cases among 134,758 postmenopausal women. There was a positive, borderline‐significant association between OC use and melanoma risk (HR = 1.12, 95% CI = 1.00-1.26), with no detected heterogeneity across countries (phomogeneity = 0.42). This risk increased linearly with duration of use (ptrend = 0.01). Among postmenopausal women, ever use of MHT was associated with a nonsignificant increase in melanoma risk overall (HR = 1.14, 95% CI = 0.97-1.43), which was heterogeneous across countries (phomogeneity = 0.05). Our findings do not support a strong and direct association between exogenous hormone use and melanoma risk. In order to better understand these relations, further research should be performed using prospectively collected data including detailed information on types of hormone, and on sun exposure, which may act as an important confounder or effect modifier on these relations. |
Note: | Versió postprint del document publicat a: https://doi.org/10.1002/ijc.32674 |
It is part of: | International Journal of Cancer, 2020, vol. 146, num. 12, p. 3267-3280 |
URI: | http://hdl.handle.net/2445/173689 |
Related resource: | https://doi.org/10.1002/ijc.32674 |
ISSN: | 0020-7136 |
Appears in Collections: | Articles publicats en revistes (Infermeria de Salut Pública, Salut mental i Maternoinfantil) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
704714.pdf | 231.05 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.